.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

All News

Biosimilars News Roundup: August 2025

September 2nd 2025

By Skylar Jeremias

Article

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

FDA Greenlights Fifth Pair of Denosumab Biosimilars: Bildyos and Bilprevda

September 2nd 2025

By Skylar Jeremias

Article

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

The Top 5 Biosimilar Articles for the Week of August 25

August 29th 2025

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27th 2025

By Skylar Jeremias

Article

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26th 2025

By Skylar Jeremias

Article

Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients.

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25th 2025

By Rose McNulty

Article

New research confirms the romiplostim biosimilar GP40141 offers comparable efficacy and safety for treating immune thrombocytopenia, enhancing treatment accessibility.

The Top 5 Biosimilar Articles for the Week of August 18

August 22nd 2025

By Skylar Jeremias

Article

Here are the top 5 biosimilar articles for the week of August 18, 2025.

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22nd 2025

By Skylar Jeremias

Article

A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

August 19th 2025

By Skylar Jeremias

Article

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative access strategies for patients.

The Top 5 Biosimilar Articles for the Week of August 11

August 15th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 11, 2025.